Aim： To evaluate the testosterone mimetic properties of icariin. Methods： Forty-eight healthy male Sprague-Dawley rats at the age of 15 months were randomly divided into four groups with 12 rats each： the control g...Aim： To evaluate the testosterone mimetic properties of icariin. Methods： Forty-eight healthy male Sprague-Dawley rats at the age of 15 months were randomly divided into four groups with 12 rats each： the control group （C）, the model group （M）, the icariin group （ICA） and the testosterone group （T）. The reproductive system was damaged by cyclophosphamide （intraperitoneal injection, 20 mg/kg·day） for 5 consecutive days for groups M, ICA and T, at the sixth day, ICA （gastric gavage, 200 mg/kg·day） for the ICA group and sterandryl （subcutaneous injection, 5 rag/rat.day） for the T group for 7 consecutive days, respectively. The levels of serum testosterone, luteinizing hormone （LH）, follicle stimulating hormone （FSH）, serum bone Gla-protein （BGP） and tartrate-resistant acid phosphatase activity in serum （StrACP） were determined. The histological changes of the testis and the penis were observed by microscope with hematoxylin-eosin （HE） staining and terminal deoxynucleotidyl transferase biotin-dUTP-X nick end labeling （TUNEL）, respectively. Results： （1） Icariin improved the condition of reproductive organs and increased the circulating levels of testosterone. （2） Icariin treatment also improved the steady-state serum BGP and might have promoted bone formation. At the same time, it decreased the serum levels of StrACP and might have reduced the bone resorption. （3） Icarrin suppressed the extent of apoptosis of penile cavernosal smooth muscle cells. Conclusion： Icariin has testosterone mimetic properties and has therapeutic potential in the management of hypoandrogenism.展开更多
Objective： To observe the efficacy and safety of Jingui Shengqi Pill （金匮肾气丸, JSP） in treating partial androgen deficiency in aging males （PADAM）, and to explore the new approach in improving the quality of l...Objective： To observe the efficacy and safety of Jingui Shengqi Pill （金匮肾气丸, JSP） in treating partial androgen deficiency in aging males （PADAM）, and to explore the new approach in improving the quality of life in PADAM patients. Methods： Forty patients with PADAM were treated with JSP, the efficacy was evaluated with international index of erectile function （IIEF） scoring, PADAM questionnaire scoring, hormone, prostatic specific antigen （PSA）, etc., and the data before treatment were compared with those after treatment in the same group. Results： After 3 months of treatment, PADAM scoring and IIEF scoring were all significantly improved. Symptoms regarding physical ability, vasomotion, and psychical and mental condition all got improved more markedly than symptoms regarding sexual hypofunction. The serum level of testosterone was 3.85±0.36 before treatment and 5.02±0.83 after treatmnet （P〈0.05）; luteinizing hormone of 7.33±2.14 and 4.84±1.43 （P〈0.01）, follicule-stimulating hormone of 10.22±4.48 and 6.47±3.28 （P〈0.01）, respectively. The level of PSA failed to change significantly （1.94±0.55 and 2.06±0.47, P〉0.05）. Conclusion： JSP is effective and safe in treating PADAM, the mechanism of it is different from supplementing extrinsic androgen. It may have produced the effect by means of favorably regulating the condition of sex hormone to improve the balance of pituitary-sex gland axis, so it has more extensive clinical application.展开更多
文摘Aim： To evaluate the testosterone mimetic properties of icariin. Methods： Forty-eight healthy male Sprague-Dawley rats at the age of 15 months were randomly divided into four groups with 12 rats each： the control group （C）, the model group （M）, the icariin group （ICA） and the testosterone group （T）. The reproductive system was damaged by cyclophosphamide （intraperitoneal injection, 20 mg/kg·day） for 5 consecutive days for groups M, ICA and T, at the sixth day, ICA （gastric gavage, 200 mg/kg·day） for the ICA group and sterandryl （subcutaneous injection, 5 rag/rat.day） for the T group for 7 consecutive days, respectively. The levels of serum testosterone, luteinizing hormone （LH）, follicle stimulating hormone （FSH）, serum bone Gla-protein （BGP） and tartrate-resistant acid phosphatase activity in serum （StrACP） were determined. The histological changes of the testis and the penis were observed by microscope with hematoxylin-eosin （HE） staining and terminal deoxynucleotidyl transferase biotin-dUTP-X nick end labeling （TUNEL）, respectively. Results： （1） Icariin improved the condition of reproductive organs and increased the circulating levels of testosterone. （2） Icariin treatment also improved the steady-state serum BGP and might have promoted bone formation. At the same time, it decreased the serum levels of StrACP and might have reduced the bone resorption. （3） Icarrin suppressed the extent of apoptosis of penile cavernosal smooth muscle cells. Conclusion： Icariin has testosterone mimetic properties and has therapeutic potential in the management of hypoandrogenism.
文摘Objective： To observe the efficacy and safety of Jingui Shengqi Pill （金匮肾气丸, JSP） in treating partial androgen deficiency in aging males （PADAM）, and to explore the new approach in improving the quality of life in PADAM patients. Methods： Forty patients with PADAM were treated with JSP, the efficacy was evaluated with international index of erectile function （IIEF） scoring, PADAM questionnaire scoring, hormone, prostatic specific antigen （PSA）, etc., and the data before treatment were compared with those after treatment in the same group. Results： After 3 months of treatment, PADAM scoring and IIEF scoring were all significantly improved. Symptoms regarding physical ability, vasomotion, and psychical and mental condition all got improved more markedly than symptoms regarding sexual hypofunction. The serum level of testosterone was 3.85±0.36 before treatment and 5.02±0.83 after treatmnet （P〈0.05）; luteinizing hormone of 7.33±2.14 and 4.84±1.43 （P〈0.01）, follicule-stimulating hormone of 10.22±4.48 and 6.47±3.28 （P〈0.01）, respectively. The level of PSA failed to change significantly （1.94±0.55 and 2.06±0.47, P〉0.05）. Conclusion： JSP is effective and safe in treating PADAM, the mechanism of it is different from supplementing extrinsic androgen. It may have produced the effect by means of favorably regulating the condition of sex hormone to improve the balance of pituitary-sex gland axis, so it has more extensive clinical application.
